We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00055367
Recruitment Status : Completed
First Posted : February 28, 2003
Last Update Posted : June 16, 2016
Elan Pharmaceuticals
Information provided by (Responsible Party):

Brief Summary:

The purpose of this study is to determine the safety and tolerability of natalizumab in adolescents (ages 12-17) diagnosed with moderately to severely active Crohn's disease (CD). It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.

Patients who complete this study may be eligible for long-term natalizumab therapy via extension protocol ELN100226-352.

Condition or disease Intervention/treatment Phase
Crohn's Disease Drug: natalizumab Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren (Natalizumab) in Adolescents With Moderately to Severely Active Crohn's Disease
Study Start Date : April 2002
Primary Completion Date : May 2004
Study Completion Date : May 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease
Drug Information available for: Natalizumab
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Male and female patients, 12-17 years of age, who have at least a six-month history of Crohn's disease and who are currently experiencing moderately to severely active Crohn's disease. Females must not be breastfeeding or pregnant, and must not become pregnant during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00055367

United States, California
Cedars-Sinai IBD Center
Los Angeles, California, United States, 90048
United States, Connecticut
Connecticut Children's Medical Center
Hartford, Connecticut, United States, 06106
United States, Florida
Miami Research Associates
Miami, Florida, United States, 33173
United States, Maryland
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21287-2631
United States, Massachusetts
Mass General Hospital for Children, Pediatric GI & Nutrition
Boston, Massachusetts, United States, 02114
The Children's Hospital
Boston, Massachusetts, United States, 02115
United States, New York
University of Rochester
Rochester, New York, United States, 14642
United States, North Carolina
Carolina Digestive Health Associates
Charlotte, North Carolina, United States, 28211
United States, Pennsylvania
Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104-4399
United States, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
United Kingdom
Royal Hospital for Sick Children
Edinburgh, United Kingdom, EH9 1LF
Royal Free Medical School
London, United Kingdom, NWS 2QG
Sponsors and Collaborators
Elan Pharmaceuticals

Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT00055367     History of Changes
Other Study ID Numbers: CD305
First Posted: February 28, 2003    Key Record Dates
Last Update Posted: June 16, 2016
Last Verified: March 2012

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Immunologic Factors
Physiological Effects of Drugs